SOUTH BRUNSWICK, N.J., Sept. 23 /PRNewswire/ -- Tris Pharma, a privately- owned, specialty pharmaceutical company, today announced that the expansion to its state-of-the-art research and manufacturing facility in South Brunswick is complete. This capacity-building initiative is a significant milestone for the company, marking its continued growth and success as a partner and provider of innovative drug delivery technologies..

The expansion provides approximately 15,000 square feet of additional space to the company's premises and current FDA-compliant cGMP facility. It allows for additional commercial-scale equipment and a new, larger warehouse that frees up space for a high-speed packaging area. This continued growth showcases Tris Pharma's momentum, and follows the company's successful clearance of its first FDA pre-approval inspection, which it passed without any deficiencies or 483s. .

"These recent events show that the company is on a steady and stable path as charted," says Ketan Mehta, CEO and Founder of Tris Pharma. "FDA's assurance of our facilities and the recent investment in our capabilities means we have ample infrastructure with which to leverage our exciting pipeline of drug delivery technologies and services."

As pharmaceutical companies search for new ways to competitively differentiate their products, Tris Pharma's increased capacity enhances its position as a partner of choice and allows it to provide more value to companies seeking to expand their product portfolio or maximize their products' lifecycle.

"Tris Pharma's recent enhancements mean that now we can provide even more services to the pharmaceutical industry," says Scott Groner, Director of Regulatory Affairs and Compliance for Tris Pharma. "It also shows that, as our partners grow, we are growing along with them."

About Tris Pharma:

Tris Pharma is a privately owned, product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms where by patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 30 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey. For more information visit http://www.trispharma.com

SOURCE Tris Pharma